Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it has filed two international patent applications under the Patent Coorperation Treaty (“PCT”) for the protection of certain of Mindset’s non-hallucinogenic novel non-tryptamine compounds known as “Family 6.”
The filings are based on pre-clinical studies and provide Mindset with preliminary freedom to operate for all claimed drug candidates from Family 6.
Additionally, by reducing or removing the psychedelic effect, in-clinic supervision should not be necessary, in turn reducing cost and improving convenience of these treatment options. The pre-clinical study results underpinning the candidates identified in these patent applications are highly promising.
Work performed on these novel non-tryptamine candidates, which included in-vitro screening, and ADME (absorption, distribution, metabolism, and excretion), along with in vivo studies, indicates 5-HT2A serotonin receptor activation without the cardinal in vivo signs of a hallucinogenic effect.James Lanthier, CEO of Mindset Pharma
Mindset’s CEO and CSO discussing the Announcement:
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds.
The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
Ecora (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) notes the announcement on 4 September by Vale Base Metals that it has…
Highlights • A$14.1M Entitlement Offer received strong demand from Australian, Canadian and international shareholders •…
Ecora Resources PLC (LSE:ECOR)(TSX:ECOR)(OTCQX:ECRAF) announced half year results for the six months ended 30 June…
First Nordic Metals Corp. (TSXV: FNM) (FNSE: FNMC SDB) (OTCQB: FNMCF) (FRA: HEG0) announced the…
Ecora (LSE/TSX: ECOR, OTCQX: ECRAF) announced that it has agreed to sell a wholly-owned subsidiary,…
Power Metallic Mines Inc. (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) announced the appointment of Seamus…